Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase with thrombospondin type 1 motif 20 (ADAMTS20) is a member of the secreted ADAMTS family of zinc-dependent metalloproteases characterized by their modular structure, including multiple thrombospondin type 1 repeats. ADAMTS20 is primarily found in the extracellular matrix, where it participates in tissue remodeling by cleaving proteoglycans such as versican, contributing to processes like regression of interdigital webs and organogenesis. Recent findings also indicate a non-canonical role in ciliogenesis, where ADAMTS20, together with ADAMTS9, is involved in primary cilium formation and maintenance in specific cell types, likely impacting signaling pathways like Hedgehog. Mutations or inactivation in model organisms result in various developmental anomalies. No direct drug interactions, biomarker roles, or mechanisms of action in therapeutics have been established, but its functions suggest it may have future implications as a therapeutic target in fibrotic, developmental, or matrix-associated diseases[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase with thrombospondin type 1 motif 20 (ADAMTS20).